Q-omics provides the consensus-scored HOXB9 profile across patient tissues and cancer cell-line models. HOXB9 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HOXB9 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, HOXB9 RNA expression shows 13,517 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KIRC, and KICH as cancer lineages where HOXB9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXB9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXB9 survival associations across molecular data types. HOXB9 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXB9 RNA expression–survival associations across cancer types. High HOXB9 expression shows unfavorable associations in KIRC, HNSC, MESO, KIRP, ACC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HOXB9 RNA expression.
This table summarizes HOXB9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXB9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXB9 shows lower tumor expression in KIRC and KICH and higher tumor expression in HNSC, STAD, UCEC and LUAD. The KIRC box plot shows higher HOXB9 RNA expression in normal versus tumor tissue (log2 FC = −4.209, t-test p < 0.001).
This table shows molecular features associated with HOXB9 in patient tissues and cancer cell lines. In patient samples, HOXB9 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXB9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
